ELVNHealthcare · BiotechnologyThe 12 Wall Street analysts covering Enliven Therapeutics, Inc. hold a median 12-month price target of $74 — +21.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Enliven Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.
Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ELVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +21.0% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | Barclays | Initiates | Overweight | $78 |
| 18 Aug 2026 | Mizuho | Maintains | Outperform | $62 → $73 |
| 18 Aug 2026 | William Blair | Initiates | Outperform | — |
| 6 Aug 2026 | Goldman Sachs | Maintains | Buy | $67 → $80 |
| 6 Aug 2026 | Goldman Sachs | Maintains | Buy | — |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $80 → $78 |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 6 Aug 2026 | Stifel | Maintains | Buy | — |
| 6 Aug 2026 | Stifel | Maintains | Buy | $80 → $82 |
| 21 July 2026 | Goldman Sachs | Maintains | Buy | — |
| 21 July 2026 | Goldman Sachs | Maintains | Buy | $59 → $67 |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | $56 → $64 |
| 1 July 2026 | Stifel | Maintains | Buy | — |
| 29 June 2026 | Jones Trading | Maintains | Buy | — |
| 9 June 2026 | Stifel | Initiates | Buy | — |
| 2 June 2026 | Mizuho | Maintains | Outperform | — |
| 8 May 2026 | Goldman Sachs | Maintains | Buy | — |
| 26 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Mar 2026 | Mizuho | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELVN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Enliven Therapeutics, Inc. returned +193.3% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 23% of US stocks
Cheaper than 91% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 33% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Enliven Therapeutics, Inc. has a market value of $4.4B and an enterprise value of $3.5B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$105.9M.
Diluted earnings per share, trailing twelve months: $−1.67.
Free cash flow in the twelve months to 30 June 2026: −$67.0M.
Trailing P/E: −32.7×; forward P/E: −25.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Enliven Therapeutics, Inc. employs 67 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Enliven Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
William Blair initiated coverage on Enliven Therapeutics with an Outperform rating, citing the potential of its lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).
Why it matters — The analyst initiation highlights growing external confidence in Enliven's lead drug candidate and its potential to disrupt the CML treatment market.
Enliven Therapeutics reported second quarter 2026 financial results and a business update, disclosing positive Phase 1 clinical data for ELVN-001 in chronic myeloid leukemia (CML) with encouraging efficacy and a favorable safety profile. The company also announced alignment with the FDA on key Phase 3 trial design components and reported $895 million in cash, cash equivalents and marketable securities, expected to fund operations into 2030.
Why it matters — The positive Phase 1 data, FDA alignment on the Phase 3 design, and a cash runway into 2030 signal meaningful clinical and regulatory progress for ELVN's lead program and its financial staying power.
The 12 Wall Street analysts covering Enliven Therapeutics, Inc. have a median 12-month price target of $74, with estimates ranging from $64 to $82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Enliven Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enliven Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Enliven Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +21.0% from the last close, and Ticker Nerd's factor model ranks Enliven Therapeutics, Inc. 68 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Enliven Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $64 to $82 over the next 12 months.
Enliven Therapeutics, Inc. returned +193.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Enliven Therapeutics Inc. is a biotechnology company dedicated to the development of novel therapeutic solutions targeting specific diseases.
The most recent item we track (Benzinga, 18 Aug 2026): "Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says". William Blair initiated coverage on Enliven Therapeutics with an Outperform rating, citing the potential of its lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).
Enliven Therapeutics Inc. is a biotechnology company dedicated to the development of novel therapeutic solutions targeting specific diseases. The primary focus of the company lies in advancing the field of precision medicine, which aims to tailor medical treatment to the individual characteristics of each patient, enhancing treatment efficacy and minimizing side effects. Enliven Therapeutics Inc. is actively engaged in researching and developing targeted therapies that address unmet medical needs across various therapeutic areas, particularly concentrating on genetic disorders and oncology. By leveraging cutting-edge technology platforms and innovative research methodologies, Enliven Therapeutics seeks to offer groundbreaking treatments that have a significant impact on patient care and outcomes. The company plays a vital role in the pharmaceutical and healthcare sectors, contributing to the rapid evolution of personalized healthcare solutions. In the financial market, Enliven Therapeutics represents an integral component of the biotechnology sector, often garnering interest from investors focused on emerging biotech innovations and their potential to transform traditional medical practices.
CEO Mr. Richard A. Fair M.B.A. · 67 employees · United States · https://www.enliventherapeutics.com
